Kirstine Stochholm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4506246/publications.pdf

Version: 2024-02-01

68 papers

3,688 citations

28 h-index 59 g-index

70 all docs

70 docs citations

times ranked

70

3488 citing authors

#	Article	IF	CITATIONS
1	Ocular morbidity in Marfan syndrome: a nationwide epidemiological study. British Journal of Ophthalmology, 2023, 107, 1051-1055.	2.1	2
2	Disorders of the eye, ear, skin, and nervous system in women with Turner syndrome –a nationwide cohort study. European Journal of Human Genetics, 2022, 30, 229-236.	1.4	9
3	The comorbidity landscape of 47,XXX syndrome: A nationwide epidemiologic study. Genetics in Medicine, 2022, 24, 475-487.	1.1	6
4	The Socioeconomic Consequences of Cushing's Syndrome: A Nationwide Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2921-e2929.	1.8	8
5	Musculoskeletal diseases in Marfan syndrome: a nationwide registry study. Orphanet Journal of Rare Diseases, 2022, 17, 118.	1.2	3
6	Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2251-e2261.	1.8	38
7	Maternal health and pregnancy outcome in diagnosed and undiagnosed Marfan syndrome: A registryâ€based study. American Journal of Medical Genetics, Part A, 2021, 185, 1414-1420.	0.7	O
8	Non-aortic cardiovascular disease in Marfan syndrome: a nationwide epidemiological study. Clinical Research in Cardiology, 2021, 110, 1106-1115.	1.5	8
9	Cancer occurrence in Turner syndrome and the effect of sex hormone substitution therapy. European Journal of Endocrinology, 2021, 184, 79-88.	1.9	23
10	Increased occurrence of liver and gastrointestinal diseases and anaemia in women with Turner syndrome – a nationwide cohort study. Alimentary Pharmacology and Therapeutics, 2021, 53, 821-829.	1.9	12
11	Sex Hormone Replacement Therapy in Turner Syndrome: Impact on Morbidity and Mortality. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 468-478.	1.8	35
12	Morbidity in 47,XYY syndrome: a nationwide epidemiological study of hospital diagnoses and medication use. Genetics in Medicine, 2020, 22, 1542-1551.	1.1	16
13	The epidemiology of sex chromosome abnormalities. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2020, 184, 202-215.	0.7	57
14	Disease Control and Gender Predict the Socioeconomic Effects of Acromegaly: A Nationwide Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2975-2982.	1.8	11
15	Revised Danish guidelines for the cancer surveillance of patients with Cowden Syndrome. European Journal of Medical Genetics, 2020, 63, 103873.	0.7	19
16	Fracture Rates and Fracture Risk in Patients With Marfan Syndrome: A Nationwide Register-Based Cohort Study. Journal of Bone and Mineral Research, 2020, 36, 901-909.	3.1	5
17	Completeness of RET testing in patients with medullary thyroid carcinoma in Denmark 1997–2013: a nationwide study. Clinical Epidemiology, 2019, Volume 11, 93-99.	1.5	7
18	Turner syndrome: mechanisms andÂmanagement. Nature Reviews Endocrinology, 2019, 15, 601-614.	4.3	179

#	Article	IF	Citations
19	Changes in the cohort composition of turner syndrome and severe non-diagnosis of Klinefelter, 47,XXX and 47,XYY syndrome: a nationwide cohort study. Orphanet Journal of Rare Diseases, 2019, 14, 16.	1.2	91
20	Survival and Long-Term Biochemical Cure in Medullary Thyroid Carcinoma in Denmark 1997–2014: A Nationwide Study. Thyroid, 2019, 29, 368-377.	2.4	43
21	Adult Care of Turner Syndrome. , 2019, , 482-489.		1
22	SUN-225 The 47,XYY Syndrome Is Associated with Increased Morbidity: A Nationwide Registry Study. Journal of the Endocrine Society, 2019, 3, .	0.1	0
23	SAT-284 Sex Hormone Replacement Therapy in Turner Syndrome and the Impact on Morbidity and Mortality. Journal of the Endocrine Society, 2019, 3, .	0.1	0
24	Morbidity, Mortality, and Socioeconomics in Females With 46,XY Disorders of Sex Development: A Nationwide Study. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1418-1428.	1.8	16
25	Longâ€ŧerm safety of growth hormone—A combined registry analysis. Clinical Endocrinology, 2018, 88, 515-528.	1.2	60
26	Incidence and prevalence of multiple endocrine neoplasia 2A in Denmark 1901–2014: a nationwide study. Clinical Epidemiology, 2018, Volume 10, 1479-1487.	1.5	19
27	Incidence and prevalence of sporadic and hereditary MTC in Denmark 1960–2014: a nationwide study. Endocrine Connections, 2018, 7, 829-839.	0.8	32
28	Causes of Mortality in the Marfan Syndrome (from a Nationwide Register Study). American Journal of Cardiology, 2018, 122, 1231-1235.	0.7	40
29	Pheochromocytoma in Denmark during 1977–2016: validating diagnosis codes and creating a national cohort using patterns of health registrations. Clinical Epidemiology, 2018, Volume 10, 683-695.	1.5	7
30	Adult Growth Hormone Deficiency: from Transition to Senescence. Pediatric Endocrinology Reviews, 2018, 16, 70-79.	1.2	2
31	Incidence and prevalence of multiple endocrine neoplasia 2B in Denmark: a nationwide study. Endocrine-Related Cancer, 2017, 24, L39-L42.	1.6	32
32	Founder Effect of the <i>RET^{C611Y}</i> Mutation in Multiple Endocrine Neoplasia 2A in Denmark: A Nationwide Study. Thyroid, 2017, 27, 1505-1510.	2.4	16
33	Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. European Journal of Endocrinology, 2017, 177, G1-G70.	1.9	771
34	Distribution of <i>RET</i> Mutations in Multiple Endocrine Neoplasia 2 in Denmark 1994–2014: A Nationwide Study. Thyroid, 2017, 27, 215-223.	2.4	29
35	Aortic events in a nationwide Marfan syndrome cohort. Clinical Research in Cardiology, 2017, 106, 105-112.	1.5	54
36	Evaluation of ICD-10 algorithms to identify hypopituitary patients in the Danish National Patient Registry. Clinical Epidemiology, 2017, Volume 9, 75-82.	1.5	2

#	Article	IF	CITATIONS
37	A Rare Case of Embryonal Carcinoma in a Patient with Turner Syndrome without Y Chromosomal Material but Mutations in <i>KIT</i> , <i> Demonstrated Using Exome Sequencing. Sexual Development, 2017, 11, 262-268.</i>	1.1	8
38	Incidence, Prevalence, Diagnostic Delay, and Clinical Presentation of Female 46,XY Disorders of Sex Development. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4532-4540.	1.8	67
39	Prevalence, incidence, and age at diagnosis in Marfan Syndrome. Orphanet Journal of Rare Diseases, 2015, 10, 153.	1.2	130
40	Growth hormone replacement does not increase mortality in patients with childhoodâ€onset growth hormone deficiency. Clinical Endocrinology, 2015, 83, 677-683.	1.2	25
41	Aggressive Medullary Thyroid Carcinoma in a Ten-Year-Old Patient with Multiple Endocrine Neoplasia 2B Due to the A883F Mutation. Thyroid, 2015, 25, 139-140.	2.4	11
42	Only a minority of sex chromosome abnormalities are detected by a national prenatal screening program for Down syndrome. Human Reproduction, 2015, 30, 2419-2426.	0.4	55
43	Reviewing the safety of GH replacement therapy in adults. Growth Hormone and IGF Research, 2015, 25, 149-157.	0.5	53
44	Patient reported outcome in posttraumatic pituitary deficiency: results from The Danish National Study on posttraumatic hypopituitarism. European Journal of Endocrinology, 2015, 172, 753-762.	1.9	17
45	Diabetes mellitus prevalence in tuberculosis patients and the background population in Guinea-Bissau: a disease burden study from the capital Bissau. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 400-407.	0.7	22
46	Multisystem Morbidity and Mortality in Offspring of Women With Type 1 Diabetes (the EPICOM Study): A Register-Based Prospective Cohort Study. Diabetes Care, 2015, 38, 821-826.	4.3	16
47	Socioeconomic Factors Do Not but GH Treatment Does Affect Mortality in Adult-Onset Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4141-4148.	1.8	16
48	Prevalence of Posttraumatic Growth Hormone Deficiency Is Highly Dependent on the Diagnostic Set-up: Results From The Danish National Study on Posttraumatic Hypopituitarism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 101-110.	1.8	64
49	Poor socio-economic status in 47,XXX – An unexpected effect of an extra X chromosome. European Journal of Medical Genetics, 2013, 56, 286-291.	0.7	17
50	Socioeconomic parameters and mortality in Turner syndrome. European Journal of Endocrinology, 2012, 166, 1013-1019.	1.9	42
51	Mortality and socioeconomic status in adults with childhood onset GH deficiency (GHD) is highly dependent on the primary cause of GHD. European Journal of Endocrinology, 2012, 167, 663-670.	1.9	15
52	Criminality in men with Klinefelter's syndrome and XYY syndrome: a cohort study. BMJ Open, 2012, 2, e000650.	0.8	62
53	Socioâ€economic factors affect mortality in 47,XYY syndrome—A comparison with the background population and Klinefelter syndrome. American Journal of Medical Genetics, Part A, 2012, 158A, 2421-2429.	0.7	25
54	Carotid intimaâ€media thickness is increased in Turner syndrome: multifactorial pathogenesis depending on age, blood pressure, cholesterol and oestrogen treatment. Clinical Endocrinology, 2012, 77, 844-851.	1.2	17

#	Article	IF	Citations
55	Left Ventricular Hypertrophy in Turner Syndrome: A Prospective Echocardiographic Study. Echocardiography, 2012, 29, 1022-1030.	0.3	13
56	Dilation of the ascending aorta in Turner syndrome - a prospective cardiovascular magnetic resonance study. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 24.	1.6	84
57	Socioeconomic Trajectories Affect Mortality in Klinefelter Syndrome. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2098-2104.	1.8	64
58	Mortality and incidence in women with 47,XXX and variants. American Journal of Medical Genetics, Part A, 2010, 152A, 367-372.	0.7	28
59	Diagnosis and mortality in 47,XYY persons: a registry study. Orphanet Journal of Rare Diseases, 2010, 5, 15.	1.2	74
60	Emerging Aspects of Turner Syndrome. European Endocrinology, 2010, 7, 58.	0.8	0
61	Morbidity and GH deficiency: a nationwide study European Journal of Endocrinology, 2008, 158, 447-457.	1.9	40
62	Mortality and Reduced Growth Hormone Secretion. Hormone Research in Paediatrics, 2007, 68, 173-176.	0.8	9
63	Mortality and GH deficiency: a nationwide study. European Journal of Endocrinology, 2007, 157, 9-18.	1.9	100
64	Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function. Pituitary, 2007, 10, 67-73.	1.6	74
65	Prevalence, Incidence, Diagnostic Delay, and Mortality in Turner Syndrome. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3897-3902.	1.8	548
66	The epidemiology of Turner syndrome. International Congress Series, 2006, 1298, 139-145.	0.2	11
67	Incidence of GH deficiency – a nationwide study. European Journal of Endocrinology, 2006, 155, 61-71.	1.9	94
68	Clinical and epidemiological description of aortic dissection in Turner's syndrome. Cardiology in the Young, 2006, 16, 430-436.	0.4	233